Chattem Ban Antiperspirant Divestiture To Fund New OTC Acquisitions
This article was originally published in The Tan Sheet
Executive Summary
Chattem will use the bulk of proceeds from the Ban antiperspirant line divestiture to Andrew Jergens to fund OTC acquisitions better suited to its "niche" product portfolio, the company said Aug. 24.
You may also be interested in...
Ban Beautifully Smooth Antiperspirant Prevents Shaving Irritation – Jergens
Andrew Jergens' Ban Beautifully Smooth antiperspirant/deodorant, rolling out now, marks the first introduction under the brand since its acquisition by the Kao subsidiary in September 2000
P&G Pharma Asset Exchange For Bristol's Clairol Possible, Analyst Says
Procter & Gamble may be willing to "exchange part or all of its pharmaceutical assets along with cash" to acquire Bristol-Myers Squibb's Clairol business, Merrill Lynch analyst Heather Murren says in a May 4 report.
Ban advertising
Bozell Group (New York City) named to handle Andrew Jergens' Ban antiperspirant/deodorant line. The ad agency's existing relationship with Jergens includes accounts for Curel moisturizing lotions and the Jergens Skincare line. Jergens recently acquired Ban from Chattem for $160 mil. (1"The Tan Sheet" Aug. 28, p. 3)